醋酸甲地孕酮预防化疗引起的消化道反应的临床研究  

Megestrol Acetate Used To Prevent Chemotherapy-induced Gastrointestinal Reactions:A Clinical Trial

作　　者：侯敏[1] 臧健[1] 勾红峰[1] 蒋明[1] 邱萌[1] 毕锋[1] 易成[1] 

机构地区：[1]四川大学华西医院肿瘤中心腹部肿瘤病房,四川成都610041

出　　处：《华西医学》2009年第3期592-594,共3页West China Medical Journal

摘　　要：目的：观察醋酸甲地孕酮（MA）在预防化疗引起的消化道反应中的作用。方法：收集2007年6月～2008年6月病理学和细胞学证实的消化道恶性肿瘤60例，采用自身前后交叉对照研究，随机分为AB和BA两组。AB组第一周期止吐方案用格拉司琼＋胃复安＋MA，第二周期止吐方案用格拉司琼＋胃复安；BA组第一周期止吐方案用格拉司琼＋胃复安，第二周期止吐方案MA＋格拉司琼＋胃复安。结果：化疗同时配合使用MA恶心、呕吐发生率下降（P〈0．05）；恶心、呕吐程度改善（P〈0．001），并且可以预防化疗引起的急性期和延迟期恶心、呕吐反应（P〈0．05）。结论：化疗同时配合使用MA可以改善化疗患者的恶心呕吐反应。Objective：To evaluate the effectiveness of megestrol acetate prevented chemotherapy induced nausea and vomiting（CINV）. Methods： Between June 2007 to June 2008,60 patients with abdominal cancer were randomly divided into two groups：AB and BA. The patients in the AB or BA group respectively receive granisetron and metoclopramide with megestrol acetate or blank to prevent CINV. Results： Incidences of nausea and vomiting occurred less in patients who received megestrol acetate versus blank （P〈 0.05）. Patients who received megestrol acetate had better improve nausea and vomiting （ P 〈 0.001 ）, and had better prevent acute and delayed CINV （ P 〈 0. 05 ）. Conclusion ： Receiving megestrol acetate during chemotherapy can relieve CINV.

关 键 词：醋酸甲地孕酮 化疗 恶心 呕吐 

分 类 号：R735[医药卫生—肿瘤]